Trial Profile
Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent Canvaxin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2007
Price :
$35
*
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Amgen
- 07 Dec 2005 New trial record.